CC-90001

Research use only, not for human use.

CC-90001 is an orally administered c-Jun N-terminal kinase (JNK) inhibitor with bias for JNK1 over JNK2.

CC-90001 is an orally administered c-Jun N-terminal kinase (JNK) inhibitor with bias for JNK1 over JNK2.(In Vitro):CC-90001 is 12.9-fold more potent for JNK1 inhibition over JNK2 in knockout fibroblasts. CC-90001 blocks LPS-induced c-jun phosphorylation (EC50 = 480 nM).(In Vivo):CC-90001 decreases multiple measures of lung collagen and reduces disease induced increases in α-SMA to nearly baseline levels in a house dust mite model of lung fibrosis. CC-90001 (3 mg/kg b.i.d.) reduces the development of fibrosis, as evidenced by a 48% reduction in collagen and a 53% reduction in α-smooth muscle actin (α-SMA) in a steatohepatitis model.

——

——

——

MAPK/ERK Signaling

JNK

Antioxidant

——

——

1403859-14-2

321.42

C16H27N5O2

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (388.90 mM)

C[C@H](CC[C@H](C1)Nc(nc(NC(C)(C)C)nc2)c2C(N)=O)[C@@H]1O

——

(-20℃)

With Ice Pack

≥ 2 years